Business context and reporting period
Lyell Immunopharma, Inc. filed this Form 10-K for the fiscal year ended December 31, 2021. It is an early clinical-stage biotechnology company developing engineered T-cell therapies for solid tumors using its Gen-R and Epi-R platforms. It had no approved products and generated no product-sale revenue. LYL797 entered Phase 1 after the reporting year, with a trial site opening in March 2022.
Key financial metrics
Amounts below are in millions of dollars except per-share data.
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue, principally GSK collaboration | $10.7 | $7.8 |
| Research and development expense | $138.7 | $182.2 |
| General and administrative expense | $89.1 | $46.9 |
| Operating loss | $(214.8) | $(211.9) |
| Net loss | $(250.2) | $(204.5) |
| Net loss per share, basic and diluted | $(1.84) | $(15.69) |
| Net cash used in operating activities | $(126.2) | $(160.9) |
| Cash, cash equivalents and marketable securities at year-end | $898.3 | $692.6 |
| Total assets | $1,127.4 | $908.3 |
| Total liabilities | $197.6 | $189.8 |
Revenue came primarily from recognizing GSK collaboration consideration as research services were performed; it was not product revenue. Gross margin is not separately presented. The company reported no debt outstanding at December 31, 2021. Year-end cash and equivalents were $293.8 million, with $604.5 million of marketable securities. Accumulated deficit was $584.4 million.
Material changes versus the prior year
- Net loss increased $45.7 million, chiefly reflecting a $36.4 million fourth-quarter impairment of the PACT Pharma investment and higher general and administrative costs.
- Research and development expense fell $43.6 million, mainly because 2020 included the $63.6 million PACT upfront commitment and $7.5 million of acquired in-process R&D. Lower collaboration and outside-service costs were partly offset by higher facilities, technology and personnel costs.
- General and administrative expense rose $42.2 million, including a $28.6 million increase in stock-based compensation and higher litigation and public-company costs.
- Operating cash use improved by $34.6 million. The company raised $391.8 million in net IPO proceeds in June 2021; the IPO also converted approximately $1.0 billion of preferred stock into common stock.
- Weighted-average shares increased to 135.9 million from 13.3 million, largely reflecting the IPO and preferred-stock conversion; this affects comparisons of loss per share.
Outlook, risks and unusual items
- Management estimated existing cash, cash equivalents and marketable securities would fund working capital and capital expenditures into 2025, but said additional capital will be required to complete clinical development. The filing states there are no committed external funding sources.
- Pipeline milestones included LYL797’s FDA IND clearance in December 2021; LYL132’s IND clearance in January 2022; planned LYL845 IND submission in the second half of 2022; and GSK’s expectation that the LYL331 IND would likely be submitted in late 2022 or early 2023. These are plans, not guarantees.
- LyFE, the company’s cell-therapy manufacturing facility, was commissioned and qualified under cGMP in December 2021. Manufacturing scale-up, product consistency, supply availability and facility compliance remain material execution risks.
- Development is early and uncertain: clinical evidence was limited, with LYL797 just entering Phase 1 and other proprietary candidates in preclinical development. Key risks include safety events, trial delays or failure, regulatory uncertainty, competition, reliance on third parties, reimbursement, intellectual-property protection and COVID-19-related disruption.
- The company recorded a full $36.4 million impairment of its PACT Series C-1 investment in Q4 2021, citing PACT’s cash needs and inability to raise funds. Lyell’s arbitration seeking rescission of its PACT agreements and recovery of consideration had a hearing in March 2022; an outcome was expected in June 2022.
- Fred Hutch and Stanford success-payment liabilities totaled $9.5 million on the balance sheet. Their agreements can require payments in cash or, at Lyell’s discretion, publicly traded shares if specified share-price thresholds are reached; aggregate potential payments are up to $200 million to each institution.
- Operating lease liabilities totaled $67.8 million, with $104.3 million of undiscounted future lease payments before tenant-improvement allowances and imputed interest. The company also disclosed up to $37.0 million of contingent Immulus development milestones, not recorded as probable at year-end.
- The audited financial statements received an unqualified opinion. Management judged disclosure controls effective at a reasonable-assurance level; auditor attestation on internal control was not required because Lyell was an emerging growth company. A prior material weakness relating to accounting for tranche liabilities was reported as remediated.
Important facts for investors to verify
- Whether clinical trials meet enrollment, safety and efficacy objectives, and whether reported preclinical results translate into human outcomes.
- Whether the estimated cash runway into 2025 remains supportable as clinical, manufacturing and operating spending develops, and what financing may be needed.
- Progress, timing and economics of the GSK programs, including LYL132, LYL331 and any future milestone or royalty receipts.
- The outcome and potential financial recovery, if any, from the PACT arbitration, and the basis for the investment impairment.
- Potential dilution or cash requirements from stock-based compensation, success-payment agreements, leases and contingent milestone obligations.